Stay updated on ARV-471 Combo vs Letrozole Combo in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the ARV-471 Combo vs Letrozole Combo in Breast Cancer Clinical Trial page.
Latest updates to the ARV-471 Combo vs Letrozole Combo in Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check10 days agoChange DetectedThe study has been updated to include 40 locations and a new type of intervention, while the previous version had 41 locations and included a site in São Paulo, Brazil.SummaryDifference1%
- Check17 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoNo Change Detected
- Check40 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
- Check47 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.SummaryDifference2%
- Check61 days agoChange DetectedThe website has added a 'Show less' feature while removing detailed options related to participant groups, interventions, and various data fields for downloads.SummaryDifference3%
- Check68 days agoChange DetectedA new study titled 'A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3)' has been added, replacing the previous version of the study, which has been deleted.SummaryDifference4%
Stay in the know with updates to ARV-471 Combo vs Letrozole Combo in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARV-471 Combo vs Letrozole Combo in Breast Cancer Clinical Trial page.